HSBC Holdings’s Radiopharm Theranostics RADX Stock Holding History

HSBC Holdings’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$265K	Sell	61,372 -130,252	-68%	-$637K	﹤0.01%	2504
2025 Q4	$1.01M	Buy	+191,624	New	+$1.02M	﹤0.01%	1942

Other funds holding RADX

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

HSBC Holdings's RADX Position: Q1 2026 in Review

HSBC Holdings reduced its Radiopharm Theranostics (RADX) stake by 68% in Q1 2026, selling an estimated $637K and leaving 61,372 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

HSBC Holdings first reported a position in RADX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.01M in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

HSBC Holdings held 61,372 shares of Radiopharm Theranostics worth $265K as of Q1 2026.
HSBC Holdings sold 130,252 Radiopharm Theranostics shares in Q1 2026, an estimated $637K.
Radiopharm Theranostics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2504 holding.
HSBC Holdings first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 2 quarters since.
HSBC Holdings's Radiopharm Theranostics position peaked at $1.01M in Q4 2025.
7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.